Facebook
Twitter
LinkedIn
Forward
MATE ACT MODULE
This activity will provide comprehensive and up-to-date information regarding the most recent and relevant laws and clinical practice guidelines regarding the safe and effective management and treatment of pain, including opioid and other substance use disorders. The 8-course series will yield practical guidance for prescribing clinicians who manage patients with pain and/or substance use disorders, including detailed information on appropriate treatment selection and management, risk mitigation strategies, and implementation of diversion and surveillance tools for controlled substances. Completion of this activity in full will satisfy the Drug Enforcement Administration (DEA) 8-hour content training requirement for The Medication Access and Training Expansion (MATE) Act.
Target Audience
This activity is designed for All Drug Enforcement Administration (DEA)-registered practitioners who treat patients with opioid or other substance use disorders, including: physicians, nurse practitioners, physician assistants, and dentists.
Learning Objectives
- Distinguish appropriate actions for prescribers and dispensers related to the federal laws regarding prescription practices for controlled substances via in person and by way of telemedicine settings.
- Explain the appropriate use for and application of opioids and non-opioids in clinical practice, including initiation, continuation/discontinuation, forced opioid tapers, and dose escalation.
- Identify appropriate areas of clinical assessment and evaluation of treatment failure, including how to adequately analyze risks and benefits of specific dosing regimens.
- Integrate workflows that foster responsible opioid prescribing practices, incorporate appropriate risk mitigation strategies and improve the informed consent process between clinicians and patients.
- Outline best practices regarding the implementation of tools for diversion and surveillance of controlled substances.
Additional Information
Charles E. Argoff MD
Professor of Neurology
Director of Comprehensive Pain Program
Albany Medical Center
Albany, NY
Timothy J. Atkinson PharmD
National Program Manager, Pain/Opioid Pharmacy Program Specialist
VHA Pain Management, Opioid Safety, PDMP (PMOP)
Director, PGY2 Pain Management & Palliative Care Residency
Murfreesboro, TN
Jeffrey J. Bettinger PharmD
Pain Management Clinical Pharmacist
Saratoga Hospital Medical Group
Schenectady, NY
Jennifer Bolen JD
Founder/Owner
The J. Bolen Group, LLC
Lenoir City, TN
Michelle E. Brown PharmD, BCPS
Clinical Pharmacy Specialist - Pain and Opioid Stewardship
Eskenazi Health
Indianapolis, IN
Mark P. Garofoli PharmD, MBA, BCGP, CPE, CTTS
Clinical Assistant Professor & Clinical Pain Management Pharmacist
West Virginia University & West Virginia University Medicine
Morgantown, WV
Jessica E. Geiger PharmD, MS, BCPS
Clinical Pharmacy Practitioner
Palliative Care
VA Northern California
Powell, OH
Andrew C. Lodolo PharmD, BCPS, BCCCP, FCCM
Pharmacy Manager, Inpatient Services
Eskenazi Health
Indianapolis, IN
Friedhelm Sandbrink MD
National Executive Director
Pain Management, Opioid Safety, and PDMP
VHA Pain Management, Opioid Safety, PDMP (PMOP)
Murfreesboro, TN
Tanya J. Uritsky PharmD, BCPP
Opioid Stewardship Coordinator
Hospital of the University of Pennsylvania
Malvern, PA
DISCLOSURES
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
CRITERIA FOR SUCCESS
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at [email protected].
CE CREDIT PROVIDED BY AKH INC., ADVANCING KNOWLEDGE IN HEALTHCARE.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 8.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHYSICIAN ASSISTANT
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.25 AAPA Category 1 CME credits. Approval is valid until Expiration. Approval is valid until September 29, 2024. PAs should only claim credit commensurate with the extent of their participation.
NURSE PRACTITIONERS
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 8.25 contact hour(s) (which includes 8.25 hour(s) of pharmacology).
Available Credit
- 8.25 AANP Contact Hours
- 8.25 AAPA Category I CME
- 8.25 AMA PRA Category 1 Credit™
Price
Mocingbird members get an additional 10% discount on all Tarsus Medical Education - Pain Week courses. Use the discount code "MOC10" to claim the additional 10% discount before you check out from your cart.
To take this course you will be redirected to Tarsus Medical Education's website. Simply create a free account with Tarsus Medical Education in order to complete this activity. You can even use your same Mocingbird username and password to create the account.
Mocingbird is pleased to provide our members with discounted access to highly respected and awarded educational partners.